Immune-related adverse events and neutrophil-to-lymphocyte ratio are possible predictive factors for gastric cancer treated with nivolumab. This is an ASCO Meeting Abstract from the 2020 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results